Associations - FGFR3 overexpression

BIOMARKER:

FGFR3 overexpression

Entrez ID:

Related biomarkers:

‹

›

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

FGFR3 overexpression FGFR3 overexpression	Urothelial Cancer Urothelial Cancer	atezolizumab + BAY1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY1163877 Sensitive : C2
FGFR3 overexpression FGFR3 overexpression	Head and Neck Cancer Head and Neck Cancer	BAY1163877 Sensitive: C3 – Early Trials BAY1163877 Sensitive : C3
FGFR3 overexpression FGFR3 overexpression	Bladder Cancer Bladder Cancer	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D
FGFR3 overexpression FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	BAY1163877 Sensitive: D – Preclinical BAY1163877 Sensitive : D
FGFR3 overexpression FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck SCCHN	BGJ398 Sensitive: D – Preclinical BGJ398 Sensitive : D